Among these studies, adults with Lp(a) level more than 150 mmol/l [22, 23, 31, 38] or patients with LDL-C more than 100 mg/dl in the absence of cardiovascular diseases [24–26, 29] were deemed eligible to be included, while the usage of any monoclonal antibody drug targeting PCSK9 was considered as an exclusion criterion [24–27, 36, 37, 39, 40] (Supplementary Tables 4 and 5). This evidence concerns the gene PCSK9 and cardiovascular disorder.